-

06:16:19 PM

ABVC Stock News

ABVC - ABVC BioPharma Inc

03/20/23 7:00 AM

Nasdaq : ABVC

low float

ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus ® Phase II Site Initiation Visit at Srinagarind Hospital, Khon Kaen University was successfully conducted on March 9-10, 2023. ABVC BioPharma Provides Vitargus ® Update on...

RHEA-AI

neutral

03/14/23 7:00 AM

Nasdaq : ABVC

low float

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

ABVC Biopharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that BioKey, a wholly-owned subsidiary of the

RHEA-AI

very positive

02/28/23 8:30 AM

Nasdaq : ABVC

low float

ABVC BioPharma Provides 2023 Pipeline Update

via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments

RHEA-AI

neutral

02/23/23 4:16 PM

Nasdaq : ABVC

clinical triallow float

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has closed a funding agreement for gross proceeds

RHEA-AI

neutral

02/21/23 8:30 AM

Nasdaq : ABVC

low float

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that approval to initiate the Phase II study of its

RHEA-AI

very positive

01/19/23 8:30 AM

Nasdaq : ABVC

low float

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at

RHEA-AI

neutral

01/05/23 8:30 AM

Nasdaq : ABVC

clinical trialfda approvallow float

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology today announced that the US Food & Drug Administration notified the

RHEA-AI

neutral

11/17/22 8:30 AM

Nasdaq : ABVC

fda approvallow float

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Vitargus® Phase II Clinical Study Protocol

RHEA-AI

neutral

11/14/22 6:20 PM

Nasdaq : ABVC

low float

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results for the third

RHEA-AI

neutral

11/07/22 8:30 AM

Nasdaq : ABVC

low float

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that on October 20, 2022, it received a Notice of

RHEA-AI

neutral

1 2 3 4 5 6 Next

ABVC Data

IndustryPharmaceutical Preparation Manufacturing
Websiteabvcpharma.com
Security nameABVC BioPharma Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees34
Tags
- Industrial Specialties
- Process Industries
- Consumer Non-Durables
- Apparel/Footwear
- Wholesale Trade
- Industrial Machinery and Equipment Merchant Wholesalers

About ABVC BioPharma Inc

ABVC BioPharma is a clinical-stage biopharmaceutical company focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center). The company has an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development.